Oxford Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Oxford Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-54,923	Closed	-$285K	–	615
2024 Q3	$285K	Buy	+54,923	New	+$273K	0.24%	171
2020 Q1	–	Sell	-21,082	Closed	-$342K	–	1390
2019 Q4	$342K	Buy	+21,082	New	+$327K	0.01%	1389
2019 Q2	–	Sell	-35,199	Closed	-$555K	–	2002
2019 Q1	$555K	Sell	35,199 -3,848	-10%	-$66.7K	0.01%	1173
2018 Q4	$786K	Buy	+39,047	New	+$860K	0.02%	978
2018 Q2	–	Sell	-28,063	Closed	-$864K	–	1971
2018 Q1	$864K	Buy	+28,063	New	+$903K	0.02%	1003
2016 Q1	–	Sell	-57,641	Closed	-$1.99M	–	913
2015 Q4	$1.99M	Buy	+57,641	New	+$2M	0.05%	396

Other funds holding RVNC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Oxford Asset Management's RVNC Position: Q4 2024 in Review

Oxford Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 54,923 shares — an estimated $285K sold.

Oxford Asset Management first reported a position in RVNC in Q4 2015 and held it in 6 quarters. The position peaked at $1.99M in Q4 2015. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

Oxford Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
Oxford Asset Management sold 54,923 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $285K.
Oxford Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 6 quarters.
Oxford Asset Management's Revance Therapeutics, Inc. position peaked at $1.99M in Q4 2015.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Oxford Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.